CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release, including, but not limited to, the guidance provided under 2018 Financial Guidance above, are
forward-looking statements under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual
results to differ materially from those reflected in Vandas forward-looking statements include, among others, Vandas assumptions regarding its ability to continue to grow its business in the U.S., Vandas ability to complete the
clinical development and obtain regulatory approval of tradipitant for the treatment of atopic dermatitis and the treatment of gastroparesis, Vandas ability to successfully commercialize
HETLIOZ® in Europe and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of
Operations sections of Vandas annual report on Form 10-K for the fiscal year ended December 31, 2017 and quarterly report on Form 10-Q for the quarter
ended June 30, 2018, which are on file with the SEC and available on the SECs website at www.sec.gov. Additional factors may be described in those sections of Vandas quarterly report on Form
10-Q for the quarter ended September 30, 2018, to be filed with the SEC in the fourth quarter of 2018. In addition to the risks described above and in Vandas annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vandas results. There can be no assurance that the actual results or
developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are
expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in
this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future
events or otherwise.
Page 4 of 7